CAS 54965-24-1 Safe Nolvadex/Tamoxifen Citrate For Fitness For Weight Loss
Tamoxifen Citrate quick details:
- - - -
Product Name: | Tamoxifen Citrate |
Alias: | TAM;Nolvadex |
CAS No.: | 10540-29-1 |
Molecular Formula: | C26H29NO |
Molecular Weight: | 371.51 |
Purity: | 99% |
Appearance: | White power . |
Use: | Antitumor drugs raw material, suitable for breast cancer. |
Packing: | According to customer requirements for packaging |
- - - -
Tamoxifen is used to treat breast cancer that has spread to other parts of the body (metastatic breast cancer), to treat breast cancer in certain patients after surgery and radiation therapy, and to reduce the chances of breast cancer in high-risk patients.
This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.
How to use Tamoxifen Citrate
Read the Medication Guide provided by your pharmacist before you start using tamoxifen and each time you get a refill. If you have any questions, consult your doctor or pharmacist.
Take this medication by mouth with or without food, usually once or twice daily for 5 years, or as directed by your doctor. Daily dosages greater than 20 milligrams are usually divided in half and taken twice a day, in the morning and evening, or as directed by your doctor. If you are using the liquid, measure the dose carefully using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.
Dosage is based on your medical condition and response to therapy.
Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.
If you have breast cancer that has spread to other parts of the body, you may experience increased bone/cancer pain and/or disease flare-up as you start taking tamoxifen. In some cases, this may be a sign of a good response to the medication. Symptoms include increased bone pain, increased tumor size, or even new tumors. These symptoms usually disappear quickly. In any case, report these symptoms right away to your doctor.
Since this drug can be absorbed through the skin and lungs, women who are pregnant or who may become pregnant should not handle this medication or breathe the dust from the tablets. (See also Precautions section.)
- Tablets, oral 10 mg
- Tablets, oral 20 mg
Tamoxifen C max is 40 ng/mL (range, 35 to 45 ng/mL), T max is approximately 5 h after dosing, and steady state is achieved in approximately 4 wk. N-desmethyl tamoxifen C max is 15 ng/mL (range, 10 to 20 ng/mL). Steady state is achieved in approximately 8 wk.
Tamoxifen is extensively metabolized. The major metabolite is N-desmethyl tamoxifen with biological activity similar to tamoxifen. It is a substrate of CYP-450 3A, 2C9, 2D6, and an inhibitor of P-glycoprotein.
Tamoxifen half-life is 5 to 7 days; 65% of a dose is excreted over a 2-wk period, with fecal excretion as the primary route of elimination. N-desmethyl tamoxifen half-life is approximately 14 days.
Hepatic Function Impairment
The effects of reduced liver function have not been determined.
The effects of age on the pharmacokinetics of tamoxifen have not been determined.
In pediatric patients, an average steady-state C max and AUC were 187 ng/mL and 4,110 ngh/mL, respectively, and steady-state C max occurred approximately 8 h after dosing. Cl/F as body weight adjusted in female pediatric patients was approximately 2.3-fold higher than in female breast cancer patients. In the youngest cohort of female pediatric patients (2 to 6 y of age), Cl/F was 2.6-fold higher; in the oldest cohort (7 to 10.9 y of age), Cl/F was approximately 1.9-fold higher.
The effects of gender on the pharmacokinetics of tamoxifen have not been determined.
The effects of race on the pharmacokinetics of tamoxifen have not been determined.
Indications and Usage
For the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation; in women with ductal carcinoma in situ (DCIS) following breast surgery and radiation to reduce the risk of invasive breast cancer; treatment of metastatic breast cancer in women and men; to reduce the incidence of breast cancer in women at high risk of breast cancer.
Ovulation stimulation in specially selected anovulatory women desiring pregnancy; management and treatment of some types of mastalgia (eg, cyclical); malignant carci